FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317690460> ?p ?o ?g. }

• W2317690460 endingPage "320" @default.
• W2317690460 startingPage "319.3" @default.
• W2317690460 abstract "<h3>Background</h3> Interleukin-20 (IL-20), a recently identified potent pro-inflammatory, angiogenic and chemoattractive cytokine, plays a significant role in the pathogenesis of rheumatoid arthritis (RA). Activated monocytes and dendritic cells are the main source of IL-20, which is significantly up-regulated particularly in synovial fluid and synovial membrane, but to a lesser extent also in plasma, of patients with established RA. However, circulating IL-20 has not yet been studied at early stages of RA. <h3>Objectives</h3> Therefore, the aim of the current study was to characterize the role of serum levels of IL-20 in patients with recent-onset RA. <h3>Methods</h3> Serum levels of IL-20 were determined in 51 patients with recent-onset RA (symptom duration <6 months) before and 3 months after initiation of treatment with disease-modifying antirheumatic drugs, and cross-sectionally in 36 healthy controls.A majority of RA patients were treated with methotrexate and low dose glucocorticoids. Disease activity (DAS28) was assessed at baseline and at 3, 6 and 12 months. Hand/feet x-rays scored using the Sharp-van der Heijde Score (SHS) were assessed at baseline and month 12. <h3>Results</h3> After the initiation of treatment, disease activity had significantly improved (DAS28 decreased from 5.28±1.43 at baseline to 2.75±1.41 at month 3 (n=51), 2.71±1.29 at month 6 (n=49) and 2.50±1.13at month 12 (n=43). Out of 43 patients with available radiographs, 10 (23%) showed an increase in SHS after 12 months (defined as >0 SHS units). Although, there were no differences in the levels of serum IL-20 between patients with recent-onset RA and healthy controls, significant reduction of circulating IL-20 was observed after treatment (from 7.691±39.026 pg/ml at baseline to 0.996±15.502 pg/ml at month 3; p<0.0001). Although serum levels of IL-20 did not correlate with DAS28 at baseline, higher IL-20 levels predicted improvement of disease activity (decrease in DAS28) at 3 months (r= -0.317, p=0.025), but not at later time points. Furthermore, decrease in the levels of IL-20 positively correlated with the change in DAS28 over 3 months (r=0.317; p=0.025). There was no association between baseline levels or changes of IL-20 and achievement of DAS28 remission or radiographic progression. <h3>Conclusions</h3> In contrast to its local up-regulation at sites of inflammation, there was no difference in circulating levels of IL-20 in patients with recent-onset RA and healthy controls. However, higher baseline levels of IL-20 were associated with better treatment response at 3 months. We suggest that significant decrease of IL-20 levels and its association with disease activity improvement in patients with RA may reflect local reduction of activated mononuclear infiltrates within the synovial tissue following successful immunosuppressive therapy. Supported by MH CR-grant project No.10065-4 <h3>Disclosure of Interest</h3> None Declared" @default.
• W2317690460 created "2016-06-24" @default.
• W2317690460 creator A5010887266 @default.
• W2317690460 creator A5012045807 @default.
• W2317690460 creator A5019487270 @default.
• W2317690460 creator A5019756953 @default.
• W2317690460 creator A5019989453 @default.
• W2317690460 creator A5031588644 @default.
• W2317690460 creator A5034269211 @default.
• W2317690460 creator A5041679459 @default.
• W2317690460 creator A5048881704 @default.
• W2317690460 creator A5051923244 @default.
• W2317690460 creator A5056553996 @default.
• W2317690460 creator A5059542057 @default.
• W2317690460 creator A5067401973 @default.
• W2317690460 creator A5079921904 @default.
• W2317690460 creator A5089477356 @default.
• W2317690460 date "2013-06-01" @default.
• W2317690460 modified "2023-09-26" @default.
• W2317690460 title "FRI0030 Higher levels of serum interleukin-20 are associated with better response to disease-modifying antirheumatic drugs in patients with resent-onset rheumatoid arthritis" @default.
• W2317690460 doi "https://doi.org/10.1136/annrheumdis-2012-eular.2487" @default.
• W2317690460 hasPublicationYear "2013" @default.
• W2317690460 type Work @default.
• W2317690460 sameAs 2317690460 @default.
• W2317690460 citedByCount "0" @default.
• W2317690460 crossrefType "journal-article" @default.
• W2317690460 hasAuthorship W2317690460A5010887266 @default.
• W2317690460 hasAuthorship W2317690460A5012045807 @default.
• W2317690460 hasAuthorship W2317690460A5019487270 @default.
• W2317690460 hasAuthorship W2317690460A5019756953 @default.
• W2317690460 hasAuthorship W2317690460A5019989453 @default.
• W2317690460 hasAuthorship W2317690460A5031588644 @default.
• W2317690460 hasAuthorship W2317690460A5034269211 @default.
• W2317690460 hasAuthorship W2317690460A5041679459 @default.
• W2317690460 hasAuthorship W2317690460A5048881704 @default.
• W2317690460 hasAuthorship W2317690460A5051923244 @default.
• W2317690460 hasAuthorship W2317690460A5056553996 @default.
• W2317690460 hasAuthorship W2317690460A5059542057 @default.
• W2317690460 hasAuthorship W2317690460A5067401973 @default.
• W2317690460 hasAuthorship W2317690460A5079921904 @default.
• W2317690460 hasAuthorship W2317690460A5089477356 @default.
• W2317690460 hasConcept C126322002 @default.
• W2317690460 hasConcept C142724271 @default.
• W2317690460 hasConcept C198451711 @default.
• W2317690460 hasConcept C203014093 @default.
• W2317690460 hasConcept C204787440 @default.
• W2317690460 hasConcept C2776164576 @default.
• W2317690460 hasConcept C2776268809 @default.
• W2317690460 hasConcept C2777575956 @default.
• W2317690460 hasConcept C2778690821 @default.
• W2317690460 hasConcept C2780942790 @default.
• W2317690460 hasConcept C2781059491 @default.
• W2317690460 hasConcept C2908564923 @default.
• W2317690460 hasConcept C2909063479 @default.
• W2317690460 hasConcept C71924100 @default.
• W2317690460 hasConcept C90924648 @default.
• W2317690460 hasConceptScore W2317690460C126322002 @default.
• W2317690460 hasConceptScore W2317690460C142724271 @default.
• W2317690460 hasConceptScore W2317690460C198451711 @default.
• W2317690460 hasConceptScore W2317690460C203014093 @default.
• W2317690460 hasConceptScore W2317690460C204787440 @default.
• W2317690460 hasConceptScore W2317690460C2776164576 @default.
• W2317690460 hasConceptScore W2317690460C2776268809 @default.
• W2317690460 hasConceptScore W2317690460C2777575956 @default.
• W2317690460 hasConceptScore W2317690460C2778690821 @default.
• W2317690460 hasConceptScore W2317690460C2780942790 @default.
• W2317690460 hasConceptScore W2317690460C2781059491 @default.
• W2317690460 hasConceptScore W2317690460C2908564923 @default.
• W2317690460 hasConceptScore W2317690460C2909063479 @default.
• W2317690460 hasConceptScore W2317690460C71924100 @default.
• W2317690460 hasConceptScore W2317690460C90924648 @default.
• W2317690460 hasIssue "Suppl 3" @default.
• W2317690460 hasLocation W23176904601 @default.
• W2317690460 hasOpenAccess W2317690460 @default.
• W2317690460 hasPrimaryLocation W23176904601 @default.
• W2317690460 hasRelatedWork W1987294331 @default.
• W2317690460 hasRelatedWork W2013698535 @default.
• W2317690460 hasRelatedWork W2049114537 @default.
• W2317690460 hasRelatedWork W2062250828 @default.
• W2317690460 hasRelatedWork W2066397332 @default.
• W2317690460 hasRelatedWork W2361180466 @default.
• W2317690460 hasRelatedWork W2407670115 @default.
• W2317690460 hasRelatedWork W2519795941 @default.
• W2317690460 hasRelatedWork W2971681808 @default.
• W2317690460 hasRelatedWork W2996380604 @default.
• W2317690460 hasVolume "71" @default.
• W2317690460 isParatext "false" @default.
• W2317690460 isRetracted "false" @default.
• W2317690460 magId "2317690460" @default.
• W2317690460 workType "article" @default.